AR107044A1 - Compuesto de quinolin-3-carboxamida, composición farmacéutica que lo comprende y su uso para prepararla - Google Patents
Compuesto de quinolin-3-carboxamida, composición farmacéutica que lo comprende y su uso para prepararlaInfo
- Publication number
- AR107044A1 AR107044A1 ARP160103847A ARP160103847A AR107044A1 AR 107044 A1 AR107044 A1 AR 107044A1 AR P160103847 A ARP160103847 A AR P160103847A AR P160103847 A ARP160103847 A AR P160103847A AR 107044 A1 AR107044 A1 AR 107044A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- muscle
- fluorine
- independently selected
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000002131 composite material Substances 0.000 title 1
- BLTDCIWCFCUQCB-UHFFFAOYSA-N quinoline-3-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CN=C21 BLTDCIWCFCUQCB-UHFFFAOYSA-N 0.000 title 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 28
- 208000029549 Muscle injury Diseases 0.000 abstract 25
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 22
- 239000011737 fluorine Substances 0.000 abstract 22
- 229910052801 chlorine Inorganic materials 0.000 abstract 21
- 239000000460 chlorine Substances 0.000 abstract 21
- 229910052794 bromium Inorganic materials 0.000 abstract 19
- 125000001424 substituent group Chemical group 0.000 abstract 19
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 18
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 15
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 15
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 15
- 125000004043 oxo group Chemical group O=* 0.000 abstract 13
- -1 quinolin-3-carboxamide compound Chemical class 0.000 abstract 11
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000002393 azetidinyl group Chemical group 0.000 abstract 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 6
- 125000002971 oxazolyl group Chemical group 0.000 abstract 6
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 208000014674 injury Diseases 0.000 abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 229910052740 iodine Inorganic materials 0.000 abstract 4
- 238000001356 surgical procedure Methods 0.000 abstract 4
- 206010068871 Myotonic dystrophy Diseases 0.000 abstract 3
- 208000027418 Wounds and injury Diseases 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 3
- 230000006378 damage Effects 0.000 abstract 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract 3
- 210000003205 muscle Anatomy 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- 206010049816 Muscle tightness Diseases 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 230000003252 repetitive effect Effects 0.000 abstract 2
- 230000000472 traumatic effect Effects 0.000 abstract 2
- 230000008736 traumatic injury Effects 0.000 abstract 2
- 125000005940 1,4-dioxanyl group Chemical group 0.000 abstract 1
- 206010003694 Atrophy Diseases 0.000 abstract 1
- 229910018862 CoN Inorganic materials 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 208000029323 Congenital myotonia Diseases 0.000 abstract 1
- 208000034656 Contusions Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000034693 Laceration Diseases 0.000 abstract 1
- 206010073713 Musculoskeletal injury Diseases 0.000 abstract 1
- 208000000112 Myalgia Diseases 0.000 abstract 1
- 208000010316 Myotonia congenita Diseases 0.000 abstract 1
- 208000035955 Proximal myotonic myopathy Diseases 0.000 abstract 1
- 208000024288 Rotator Cuff injury Diseases 0.000 abstract 1
- 206010039227 Rotator cuff syndrome Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 238000002266 amputation Methods 0.000 abstract 1
- 210000001264 anterior cruciate ligament Anatomy 0.000 abstract 1
- 230000037444 atrophy Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 206010010121 compartment syndrome Diseases 0.000 abstract 1
- 238000002316 cosmetic surgery Methods 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 230000003111 delayed effect Effects 0.000 abstract 1
- 201000001981 dermatomyositis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003414 extremity Anatomy 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 238000011540 hip replacement Methods 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 238000013150 knee replacement Methods 0.000 abstract 1
- 208000013465 muscle pain Diseases 0.000 abstract 1
- 201000008709 myotonic dystrophy type 2 Diseases 0.000 abstract 1
- ONLRKTIYOMZEJM-UHFFFAOYSA-N n-methylmethanamine oxide Chemical compound C[NH+](C)[O-] ONLRKTIYOMZEJM-UHFFFAOYSA-N 0.000 abstract 1
- 230000002232 neuromuscular Effects 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 208000005987 polymyositis Diseases 0.000 abstract 1
- 230000036544 posture Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 210000000513 rotator cuff Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 210000002435 tendon Anatomy 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268630P | 2015-12-17 | 2015-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107044A1 true AR107044A1 (es) | 2018-03-14 |
Family
ID=57589094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103847A AR107044A1 (es) | 2015-12-17 | 2016-12-15 | Compuesto de quinolin-3-carboxamida, composición farmacéutica que lo comprende y su uso para prepararla |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210238162A1 (enExample) |
| EP (1) | EP3390384B1 (enExample) |
| JP (1) | JP2019502691A (enExample) |
| KR (1) | KR20180095580A (enExample) |
| CN (1) | CN108430992A (enExample) |
| AR (1) | AR107044A1 (enExample) |
| AU (1) | AU2016370779B2 (enExample) |
| BR (1) | BR112018012469B1 (enExample) |
| CA (1) | CA3008358A1 (enExample) |
| RU (1) | RU2018126105A (enExample) |
| TW (1) | TW201733988A (enExample) |
| UY (1) | UY37028A (enExample) |
| WO (1) | WO2017103851A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913880XA (en) | 2015-07-02 | 2020-03-30 | Hoffmann La Roche | Bicyclic lactams and methods of use thereof |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
| ES2884073T3 (es) | 2016-11-11 | 2021-12-10 | Bayer Animal Health Gmbh | Nuevos derivados antihelmínticos de quinolina-3-carboxamida |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| MX393318B (es) | 2017-04-18 | 2025-03-24 | Tempest Therapeutics Inc | Compuestos bicíclicos y su uso en el tratamiento del cáncer |
| EP3638672A1 (en) * | 2017-06-13 | 2020-04-22 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds as h-pgds inhibitors |
| US11254661B2 (en) | 2017-08-04 | 2022-02-22 | Bayer Animal Health Gmbh | Quinoline derivatives for treating infections with helminths |
| PT3676297T (pt) | 2017-09-01 | 2023-08-29 | Denali Therapeutics Inc | Compostos, composições e métodos |
| CN111479814A (zh) * | 2017-12-13 | 2020-07-31 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为h-pgds抑制剂的稠合的吡啶 |
| EP3692037A1 (en) | 2017-12-15 | 2020-08-12 | Bayer Animal Health GmbH | Process for preparing antihelmintic 4-amino-quinoline-3-carboxamide derivatives |
| CA3096894A1 (en) * | 2018-04-17 | 2019-10-24 | Tempest Therapeutics, Inc. | Bicyclic carboxamides and methods of use thereof |
| EP3781571B1 (en) * | 2018-04-20 | 2024-01-17 | F. Hoffmann-La Roche AG | N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| SG11202010024UA (en) | 2018-05-09 | 2020-11-27 | Bayer Animal Health Gmbh | New quinoline derivatives |
| US20220177456A1 (en) * | 2019-03-06 | 2022-06-09 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| WO2021204930A1 (en) | 2020-04-09 | 2021-10-14 | Bayer Animal Health Gmbh | Substituted condensed azines as anthelmintic compounds |
| CN111549000B (zh) * | 2020-06-18 | 2022-07-29 | 中国医学科学院整形外科医院 | 一种过表达Hpgds的重组脂肪干细胞、制备方法及其应用 |
| US20230339937A1 (en) | 2020-06-19 | 2023-10-26 | Sato Pharmaceutical Co., Ltd. | Condensed ring compounds that inhibit h-pgds |
| US20230348394A1 (en) * | 2020-09-11 | 2023-11-02 | The Regents Of The University Of California | Compositions and methods for treating muscular dystrophies |
| JP2024521786A (ja) * | 2021-05-28 | 2024-06-04 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｂｔｋ阻害剤及びその中間体の合成 |
| EP4148052A1 (en) | 2021-09-09 | 2023-03-15 | Bayer Animal Health GmbH | New quinoline derivatives |
| US20250074906A1 (en) | 2021-12-17 | 2025-03-06 | Sato Pharmaceutical Co., Ltd. | Azaindole derivative that inhibits h-pgds |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69413955T2 (de) | 1993-03-17 | 1999-04-01 | Minnesota Mining And Mfg. Co., Saint Paul, Minn. | Aerosolzusammensetzung enthaltend einen aus ester-, amid- oder merkaptoester- derivat dispergiermittel |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| CA2376024A1 (en) * | 1999-06-02 | 2000-12-07 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
| WO2005094805A1 (ja) * | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
| TW200720255A (en) | 2005-07-13 | 2007-06-01 | Taiho Pharmaceutical Co Ltd | Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
| JP2007051121A (ja) | 2005-07-22 | 2007-03-01 | Taiho Yakuhin Kogyo Kk | プロスタグランジンｄ合成酵素を阻害するピリミジン化合物 |
| DOP2006000210A (es) | 2005-10-04 | 2007-06-15 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| JP2010513458A (ja) * | 2006-12-19 | 2010-04-30 | ファイザー・プロダクツ・インク | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用 |
| BRPI0809974A2 (pt) | 2007-03-30 | 2014-10-07 | Sanofi Aventis | Compostos de pirimidina hidrazida como inibidores de pgds |
| GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| US8129390B2 (en) * | 2007-12-12 | 2012-03-06 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds and methods for using the same |
| CA2725481A1 (en) * | 2008-06-18 | 2009-12-23 | Pfizer Limited | Nicotinamide derivatives |
| TW201010997A (en) * | 2008-06-18 | 2010-03-16 | Pfizer Ltd | Nicotinamide derivatives |
| WO2010033977A2 (en) | 2008-09-22 | 2010-03-25 | Cayman Chemical Company | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| MX2011009423A (es) | 2009-03-09 | 2011-09-28 | Taiho Pharmaceutical Co Ltd | Compuesto de piperazina capaz de inhibir prostaglandina d sintasa. |
| EP2487175A1 (en) | 2009-10-06 | 2012-08-15 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical product containing aromatic heterocyclic compound |
| BR112012007635B1 (pt) | 2009-10-08 | 2019-07-09 | Sanofi | Compostos derivados de feniloxadiazol como inibidores de pgds, composição farmacêutica compreendendo os mesmos e seus processos de preparação |
| MY161134A (en) | 2010-01-22 | 2017-04-14 | Taiho Pharmaceutical Co Ltd | Piperazine compound having a pgds inhibitory effect |
| US9212209B2 (en) * | 2012-07-13 | 2015-12-15 | Indiana University Research And Technology Corporation | Screening methods for spinal muscular atrophy |
-
2016
- 2016-12-15 CA CA3008358A patent/CA3008358A1/en not_active Abandoned
- 2016-12-15 TW TW105141512A patent/TW201733988A/zh unknown
- 2016-12-15 AR ARP160103847A patent/AR107044A1/es unknown
- 2016-12-15 RU RU2018126105A patent/RU2018126105A/ru not_active Application Discontinuation
- 2016-12-15 BR BR112018012469-9A patent/BR112018012469B1/pt not_active IP Right Cessation
- 2016-12-15 KR KR1020187019904A patent/KR20180095580A/ko not_active Withdrawn
- 2016-12-15 UY UY0001037028A patent/UY37028A/es unknown
- 2016-12-15 WO PCT/IB2016/057676 patent/WO2017103851A1/en not_active Ceased
- 2016-12-15 US US16/062,223 patent/US20210238162A1/en not_active Abandoned
- 2016-12-15 CN CN201680074158.0A patent/CN108430992A/zh active Pending
- 2016-12-15 EP EP16815960.6A patent/EP3390384B1/en active Active
- 2016-12-15 JP JP2018531378A patent/JP2019502691A/ja active Pending
- 2016-12-15 AU AU2016370779A patent/AU2016370779B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018012469B1 (pt) | 2020-11-24 |
| TW201733988A (zh) | 2017-10-01 |
| RU2018126105A (ru) | 2020-01-17 |
| AU2016370779A1 (en) | 2018-06-14 |
| AU2016370779B2 (en) | 2019-07-25 |
| EP3390384A1 (en) | 2018-10-24 |
| WO2017103851A1 (en) | 2017-06-22 |
| US20210238162A1 (en) | 2021-08-05 |
| EP3390384B1 (en) | 2021-09-15 |
| UY37028A (es) | 2017-07-31 |
| CN108430992A (zh) | 2018-08-21 |
| JP2019502691A (ja) | 2019-01-31 |
| BR112018012469A2 (pt) | 2018-12-18 |
| KR20180095580A (ko) | 2018-08-27 |
| CA3008358A1 (en) | 2017-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107044A1 (es) | Compuesto de quinolin-3-carboxamida, composición farmacéutica que lo comprende y su uso para prepararla | |
| AR102522A1 (es) | Variantes de región fc con propiedades modificadas de unión a fcrn y proteína a | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| EA201171197A8 (ru) | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения | |
| JP2017537940A5 (enExample) | ||
| AR092031A1 (es) | Inhibidores del canal de potasio medular externo renal | |
| MX2016014634A (es) | Compuestos para el tratamiento de enfermedades y trastornos oftalmicos. | |
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| HRP20171873T1 (hr) | Fluorinirani antagonisti integrina | |
| AR109714A1 (es) | Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostéricos negativos de mglur2, composiciones y su uso | |
| BR112015004523A2 (pt) | compostos de tetraciclina | |
| RU2018123285A (ru) | Одноразовый подгузник, применяемый при недержании | |
| CL2022000319A1 (es) | Derivados de amidas híbridas de anfotericina b | |
| RU2019139886A (ru) | Терапевтическое средство против дисфункции мейбомиевых желез | |
| EA202190057A1 (ru) | Солюбилизированные апиразы, способы и применение | |
| UY29802A1 (es) | Análogos de la feniletilamina y su uso en el tratamiento del glaucoma | |
| EA201600469A1 (ru) | Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости | |
| EA202092763A1 (ru) | Применение бисамидного производного малоновой кислоты для лечения аллергических и других заболеваний человека и животных | |
| MX2021003030A (es) | Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion. | |
| MX386153B (es) | COMPOSICIONES Y MÉTODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA ESTABILIDAD DE ARTICULACIÓN. | |
| AR109688A1 (es) | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos | |
| EA201000672A1 (ru) | Комбинезон для нейроортопедической реабилитации | |
| BR112015017381A2 (pt) | agentes analgésicos oculares tópicos | |
| Altukhova et al. | Long-term functional symptoms after total knee arthroplasty | |
| De Rover et al. | Ipsilateral tibial shaft fracture and distal tibial triplane fracture with an intact fibula: a case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |